Table 2 Response to Pembrolizumab therapy.

From: Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

 

Combined

FC

LM

Best overall response

N (%)

N (%)

N (%)

ORR (PR)

1 (3.4%)

1 (4.7%)

0

Stable disease

6 (20.7%)

4 (19.1%)

2 (25%)

Disease control rate (CR + PR + SD)

7 (24.1%)

5 (23.8%)

2 (25%)

Progressive disease

17 (58.6%)

12 (57.1%)

5 (62.5%)

Not evaluated

5 (17.2%)

4 (9.5%)

1 (12.5%)

Back to article page